Synlogic is creating a novel class of living medicines. By genetically altering non-pathogenic bacteria found naturally in the human gut, Synlogic’s medicines perform specific functions within the microbiome. Therapeutic synthesis can occur within the microbiome itself, without radically changing the human microbiota.
Number of employees: 51 – 250
Industry: Synthetic Biology
Location: Cambridge, MA, USA
Inefficient process optimization due to rigid software systems
Legacy software couldn’t keep pace with Synlogic’s need for rapid process iteration, putting the onus on scientists to manage manual data entry across disparate systems.
Conducting analyses on data scattered across digital tools
Disparate systems of record for fermentation data hindered analysis and reporting, delaying critical business decisions.
Finding the right data across siloed systems
Without a central place to store the data produced by their bioreactors, scientists spent significant time tracking people down and sending emails.